Prima BioMed (NASDAQ:PBMD) is an Australian-listed Biotech company which is cross-listed on the NASDAQ with an ADR. Given its international listing, its market cap ($125m), and, its liquidity (22k shares average, or $70k notional traded daily), it has received little exposure despite a compelling technology platform, solid cash position, and upcoming data catalysts. As management has gotten on the road and started to tell the story, the stock has responded somewhat (from $2.50 in mid-July to $3.20 at 7/30 close), but given the low volumes and overall outlook, I believe there is still room left to run…with some caveats that I will discuss later.
First, some brief background. Prima styles itself as a leader in developing personalized...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|